Cite

HARVARD Citation

    Katz, J. et al. (2022). A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS. Annals of clinical and translational neurology. 9 (1), pp. 50-66. [Online]. 
  
Back to record